Mandate

Vinge advises Ampersand Capital Partners

April 22, 2016

Vinge advises Ampersand Capital Partners, a Boston based private equity firm, in connection with the forming of the Gyros Protein Technologies group. The new group consists of Ampersand’s portfolio company Protein Technologies, Inc., a US based provider of peptide synthesis instrumentation and reagents, and the Swedish Gyros group operating within automated nanoliter-scale immunoassays, who’s majority owner is the Swedish Sixth National Pension Fund.
 
Vinge’s team consisted of, among others, the partner in charge Christina Kokko and Kristina Ekberg, Oscar Rydén and Maria Schultzberg.

Related

Vinge advises Sertion in connection with the acquisition of Kiefer System Group

Vinge has advised Sertion AB (“Sertion”) in connection with the acquisition of Kiefer System Group.
October 10, 2025

Vinge advises Main Capital and Aritma in connection with the acquisition of Programekonomi

Vinge has advised Aritma International AS (“Aritma”), a Norwegian bank-connectivity and financial automation software provider, in connection with the acquisition of Programekonomi Svenska Aktiebolag.
October 09, 2025

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025